title: A retinoic acid receptor agonist tamibarotene suppresses iron accumulation in the liver.
abstract: OBJECTIVE
  Hepatic iron overload (HIO) and iron-induced oxidative stress have recently emerged as an important factor for the development and progression of insulin resistance. The aim of this study was to evaluate the effect of tamibarotene, a selective retinoic acid receptor α/β agonist, on hepatic iron metabolism, based on our previous findings that retinoids suppress hepatic iron accumulation by increasing hepatic iron efflux through the regulation of hemojuvelin and ferroportin expression.
  
  
  METHODS
  We quantitated the non-heme iron content and iron metabolism-related gene expression in the liver, and serum lipid and blood glucose levels in KK-A(y) mice after dietary administration of tamibarotene.
  
  
  RESULTS
  It was demonstrated that tamibarotene significantly reduced blood glucose and hepatic iron, but not serum lipids, and that hemojuvelin expression significantly decreased while ferroportin increased, as observed previously.
  
  
  CONCLUSIONS
  These results suggest that tamibarotene is a promising alternative for the treatment of insulin resistance associated with HIO.
authors: Department of Biophysical Chemistry, Kyoto Pharmaceutical University, Kyoto, Japan.
authors: Osamu
authors: O
authors: Yoshikawa
authors: Yu
authors: Y
authors: Ebata
authors: Hiroyuki
authors: H
authors: Tsuchiya
authors: Arisa
authors: A
authors: Kawahara
authors: Chihiro
authors: C
authors: Kojima
authors: Yoshito
authors: Y
authors: Ikeda
authors: Susumu
authors: S
authors: Hama
authors: Kentaro
authors: K
authors: Kogure
authors: Koichi
authors: K
authors: Shudo
authors: Goshi
authors: G
authors: Shiota
mesh_terms: D000818:Animals; D001565:Benzoates / Q000494:pharmacology / Q000627:therapeutic use*; D001692:Biological Transport; D001786:Blood Glucose / Q000378:metabolism; D027682:Cation Transport Proteins / Q000378:metabolism; D015870:Gene Expression; D006418:Heme / Q000378:metabolism; D006432:Hemochromatosis / Q000378:metabolism / Q000517:prevention & control*; D007333:Insulin Resistance; D007501:Iron / Q000378:metabolism*; D019190:Iron Overload / Q000378:metabolism / Q000517:prevention & control*; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D018384:Oxidative Stress; D018168:Receptors, Retinoic Acid / Q000819:agonists*; D000072482:Retinoic Acid Receptor alpha; D013764:Tetrahydronaphthalenes / Q000494:pharmacology / Q000627:therapeutic use*; D000098742:Ferroportin
chemical_list: D001565:Benzoates; D001786:Blood Glucose; D027682:Cation Transport Proteins; D008055:Lipids; C000607072:Rara protein, mouse; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D013764:Tetrahydronaphthalenes; D000098742:Ferroportin; C082925:retinoic acid receptor beta; C061133:tamibarotene; D006418:Heme; D007501:Iron